GOT1 and familial pancreatic carcinoma: Zhou reported that circ-MBOAT2 modulates tumor development and glutamine catabolism via the miR-433-3p/GOT1 axis in pancreatic cancer, suggesting circ-MBOAT2 may be a therapeutic target for pancreatic cancer [60].